ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM
Abstract Number: 2987
An EULAR Study Group Pilot Study on Reliability of Simple� Capillaroscopic Definitions to Describe Capillary Morphology in Rheumatic Diseases
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III
9:00AM-11:00AM
Abstract Number: 2701
An Expansion of Rare Lineage Intestinal Microbes Characterize Rheumatoid Arthritis
Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2707
An in Vitro Bovine Bone Chip Model with Micro-CT: A Model for the Assessment of Autoantibody Mediated Bone Resorption
Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2423
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions
9:00AM-11:00AM
Abstract Number: 2382
An Outsourced Health-Enhancing Physical Activity Program for People with Rheumatoid Arthritis. Exploration of the Maintenance Phase
Orthopedics, Low Back Pain and Rehabilitation Poster (ARHP): Rehabilitation Sciences
9:00AM-11:00AM
Abstract Number: 2827
Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 2656
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rheumatoid Arthritis - Clinical Aspects Poster Session III
9:00AM-11:00AM
Abstract Number: 2916
Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III
9:00AM-11:00AM
Abstract Number: 2377
Anti  3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase in Systremic Sclerosis
Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 2433
Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions
9:00AM-11:00AM
Abstract Number: 2456
Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ARHP): Pediatrics
9:00AM-11:00AM
Abstract Number: 2364
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive Myopathy Patients without Statin Exposure May Have a Progressive Disease That Worsens Despite Aggressive Immunosuppressive Therapy
Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies
9:00AM-11:00AM
Abstract Number: 3045
Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Vasculitis Poster III
9:00AM-11:00AM
Abstract Number: 2590
Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Rheumatoid Arthritis - Clinical Aspects Poster Session III
9:00AM-11:00AM
Abstract Number: 2607
Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Rheumatoid Arthritis - Clinical Aspects Poster Session III
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 72
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology